Same Industry, Less Money: What Insulet Offers That Intuitive Surgical Does Not
In the world of medical technology, paying a premium for quality is common, but what happens when a cheaper rival is also growing faster?
The market charges 41.8 times operating profit for a dollar of Intuitive Surgical (ISRG)’s earnings, but only 22.0 times for a dollar from its Health Care Equipment peer, Insulet (PODD). These are two ways to own a piece of the medical device future, yet the market has persistently valued one far more richly than the other, even as the cheaper company grows faster. The question for an investor is what, exactly, that premium on Intuitive Surgical still buys.
The premium buys a dominant and profitable platform.
Intuitive Surgical’s valuation is built on a foundation of scale and profitability that its peer has not matched. ISRG converts revenue into operating profit at a rate of 30.5%, far ahead of Insulet’s 17.5% margin. This is no historical artifact; it is a function of a deeply entrenched ecosystem. The company’s recurring revenue now accounts for 86% of its total, a testament to the long-term relationships built around its installed base of surgical systems.
- 5 S&P 500 Stocks Hit 52-Week Lows On Tuesday
- The Paid-To-Hold Play On ISRG Stock: A 12% Income
- ISRG Stock: What Does Its Valuation Imply?
- Just How Much Risk Is Built Into ISRG Stock?
- Just How Wide Is The Path Ahead For Intuitive Surgical Stock?
- Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.
That base is also becoming more productive. The new da Vinci 5 systems show utilization approximately 11% higher than the previous generation, driving efficiency for hospitals and more procedures for Intuitive. Management calls this “innovation-led revenue performance,” and their confidence is reflected in their guidance for both 2026 procedure growth and gross profit margin. This is the core of the bull case: you are paying for a market leader with a proven, high-margin, and expanding moat.
The key numbers side by side, today:
| Metric | ISRG | PODD |
|---|---|---|
| P/OpInc* | 41.8x | 22.0x |
| LTM OpInc Growth | 31.1% | 48.9% |
| 3Y Avg OpInc Growth | 27.6% | 298.5% |
| LTM Revenue Growth | 21.4% | 31.9% |
| 3Y Avg Revenue Growth | 18.1% | 28.5% |
OpInc = Operating Income, P/EBIT = Price To Operating Income Ratio
And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:
| Metric | ISRG | PODD |
|---|---|---|
| P/OpInc* | 61.8x | 43.1x |
| LTM OpInc Growth | 25.4% | 53.4% |
| 3Y Avg OpInc Growth | 23.5% | 193.0% |
| LTM Revenue Growth | 20.5% | 30.7% |
| 3Y Avg Revenue Growth | 17.4% | 27.6% |
OpInc = Operating Income
Paying less buys faster growth and fewer pressures.
The case against the premium rests on the live business an investor can own for nearly half the price per dollar of profit. Beyond being cheaper, Insulet is growing significantly faster, with revenue up 31.9% over the last twelve months compared to 21.4% for Intuitive. Critically, Insulet also issued forward guidance for revenue growth at its last report, signaling management’s optimism about the future.
While Intuitive Surgical navigates a complex global landscape, including “ongoing challenges in China and Japan,” Insulet is expanding its own patient-centric ecosystem, recently partnering with the mental health company Calm to provide well-being resources for the diabetes community. An investor in the cheaper, faster-growing peer also sidesteps some of ISRG’s specific pressures, such as the roughly 10% decline in U.S. bariatric procedures, which management attributes to the growth in GLP-1 drugs. The question of how wide the path ahead is for Intuitive Surgical is a key consideration for investors weighing its current valuation.
The choice turns on proven dominance versus disruptive growth.
Ultimately, the decision comes down to a trade-off between an established, highly profitable incumbent and a nimbler, faster-growing challenger. The premium on Intuitive Surgical is the price of its vast installed base, its powerful recurring revenue model, and its demonstrated ability to innovate within its ecosystem. The discount on Insulet is an opportunity to own faster top-line growth without the complexities of a global giant.
The single most important test for ISRG’s premium will be its ability to deliver on its own procedure growth forecast. Management has guided for full-year 2026 da Vinci procedure growth to land between 13.5% and 15.5%. Whether the company can hit the high end of that range, despite acknowledged pressures, will be the clearest signal of whether its dominant platform still merits its dominant multiple. The decision is yours.
Want To Stack Them Up Side By Side Yourself?
You can line Intuitive Surgical and Insulet up directly on the Intuitive Surgical peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Health Care Equipment names you hold. Or, if you would rather not pick a side at all, a healthcare ETF like XLV holds both Intuitive Surgical and Insulet alongside the rest of the group.
The Better Bet Is Still One Bet
Picking the statistically better stock improves the odds, it does not change how much rides on one name. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.